8-K
filed May 7, 2026, 7:59 PM ET
ticker GMED
CIK 0001237831
earnings
confidence high
sentiment positive
materiality 0.75
Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80
GLOBUS MEDICAL INC
2026-Q1 EPS reported
$0.90
revenue$759,854,000
- GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).
- Worldwide net sales $759.9M, up 27% as-reported; base business (ex-Nevro) up 13.2%.
- FY2026 revenue guidance reaffirmed at $3.18B–$3.22B; non-GAAP EPS guidance raised to $4.70–$4.80 from $4.40–$4.50.
- U.S. net sales +25% YoY; international +35.6% as-reported (+27.8% constant currency).
- Operating margin expanded on manufacturing initiatives and operating leverage.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
GLOBUS MEDICAL INC reported the first quarter ended March 31, 2026 results: revenue $759.9 million, net income $124.3 million, EPS $0.90.
- Period
- the first quarter ended March 31, 2026
- Revenue
- $759.9 million
- Net income
- $124.3 million
- EPS
- $0.90
- Result
- reported results
Exact text from the filing
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: • Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. • Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. • GAAP net income for the quarter was $124.3 million. • GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
GLOBUS MEDICAL INC reported full-year 2026 results: revenue $3.18 billion to $3.22 billion, EPS $4.70 to $4.80. Guidance raised.
- Period
- full-year 2026
- Revenue
- $3.18 billion to $3.22 billion
- EPS
- $4.70 to $4.80
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.